Dabigatran etexilate in clinical practice for prevention of thromboembolic events in patients with atrial fibrillation

Czech version

Authors: M. Táborský ^1,2; P. Heinc ^1,2; Y. Hrčková ^1,2
Authors‘ workplace: I. interní klinika – kardiologická Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr, Miloš Táborský, Ph. D., FESC, MBA ¹; Komplexní kardiovaskulární centrum FN Olomouc, přednosta prof. MUDr. Petr Bachleda, CSc. ²
Published in: Vnitř Lék 2012; 58(10): 769-777
Category: Reviews

Overview

Dabigatrane is the first new generation antiacoagulant that at a dose of 150 mg twice daily was, in the RE-LY study, more effective in cerebrovascular event and systemic embolisation prevention than well-controlled warfarin and had comparable or better safety profile than well-controlled warfarin. The 110 mg twice daily dose showed comparable efficacy and superior safety against warfarin. Crucial and unique among modern anticoagulants is its ability to significantly reduce ischemic as well as hemorrhagic CVEs at a dose of 150 mg twice daily. In addition, dabigatran significantly facilitates management of patients with atrial fibrillation as it does not require laboratory monitoring, has predictable pharmacokinetics, simple dosing regimen that does not require complicated dose adjustments, and does not interact with food. However, it is important to remember that it is an anticoagulant. Care should, therefore, be exercised when the treatment is indicated, renal function has to be known and it needs to be kept in mind that, as with any anticoagulant, the treatment may be associated with bleeding. However, when indication criteria are observed, the above listed advantages considered and careful patient monitoring put in place, the bleeding will be, compared to standard warfarin treatment, minimized.

Key words:
dabigatran – atrial fibrillation – tromboembolism

Sources

1. DeWilde S, Carey IM, Emmas C et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 1064–1070.

2. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–2429.

3. European Medicines Agency. Science Medicines Health. Pradaxa – dabigatran etexilate. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf.

4. Čihák R, Heinc P, Haman L et al. Doporučený postup ČKS pro léčbu fibrilace síní. Cor Vasa 2011; 53 (Suppl 1): 27–52.

5. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

6. Lip GY, Frison L, Halperin JL et al. Identifying patients at high risk of stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731–2738.

7. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875–1876.

8. European Medicines Agency. Science Medicines Health. Pradaxa – dabigatran etexilate. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.sjsp&jsenabled=true.

9. You JJ, Singer D, Howard PA et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): e531S–e575S.

10. Státní ústav pro kontrolu léčiv. Pradaxa. Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0168373&tab=prices.

11. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386–399.

12. Reilly PA, Conrad CA, Faaij RA et al. Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial. Eur Heart J 2011; 32 (Suppl 1): 6. Abstract 129.

13. Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects. Eur Heart J 2011; 32 (Suppl 1): 618–619. Abstract P3566.

14. Huisman MV, Lip GY, Diener HC et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838–847.

15. Oldgren J, Alings M, Darius H et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660–667.

16. Eikelboom J, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–2372.

17. van Ryn J, Neubauer M, Flieg R et al. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Pathophysiol Haemost Thromb 2010; 57 (Suppl 1): A94. Abstract P485.

18. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478–e534.

19. De Smedt A, De Raedt S, Nieboer K et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533–534.

20. Matute MC, Guillán M, García-Caldentey J et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178–179.

21. van Ryn J, Litzenburger T, Waterman A et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models free. J Am Coll Cardiol 2011; 57 (Suppl 1): E1130.

22. Lu G, Deguzman FR, Karbarz MJ et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445). Eur Heart J 2011; 32: 640–641. Abstract 3712.

23. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–1579.

24. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397–402.

25. Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012; 125: 669–676.

26. Da Caterina R, Husted S, Wallentin L et al. New oral anticoagulans in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59: 1413–1425.

27. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131–136.

28. Winkle RA, Mead RH, Engel G et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264–268.

29. Maegdefessel L, Linde T, Krapiec F et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing trombus formation on mechanical heart valves. Thromb Res 2010; 126: e196–e200.

30. McKellar SH, Abel S, Camp CL et al. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011; 141: 1410–1416.

31. RE-ALIGN: A randomised, phase II study to evaluate the safety of oral dabigatran etexilate in patients after heart valve replacement. Available from: NCT01452347. www.clinicaltrials.gov.

32. O lécích.cz. Hlášení pro SÚKL. Dostupné z: http://www.olecich.cz/hlaseni-pro-sukl/nahlasit-nezadouci-ucinek.

33. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–1127.